Chang I-Wei, Li Chien-Feng, Lin Victor Chia-Hsiang, He Hong-Lin, Liang Per-In, Wu Wen-Jeng, Li Ching-Chia, Huang Chun-Nung
1. Department of Pathology, E-DA Hospital, I-Shou University, Kaohsiung, Taiwan;; 2. School of Medicine for International Students, I-Shou University, Kaohsiung, Taiwan;
3. Department of Pathology, Chi-Mei Medical Center, Tainan, Taiwan;; 4. Department of Biotechnology, Southern Taiwan University of Science and Technology, Tainan, Taiwan;; 5. Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan;; 6. National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan;
J Cancer. 2016 Jul 8;7(11):1541-9. doi: 10.7150/jca.15696. eCollection 2016.
Urothelial carcinoma (UC) is a type of tumor, especially of the urinary bladder, that affects people worldwide. Clarification of its detailed tumor biology and discovery of potential targets for developing treatment strategies are imperative because of frequent recurrences and poor prognosis of advanced UCs. By data mining a published dataset of UC of bladder (UCB) transcriptome (GSE31684) from Gene Expression Omnibus, National Center of Biotechnology Information (GEO, NCBI), we identified that THBS2 was the most significantly upregulated gene among those related to structural molecule activity (GO:0005198). Therefore, we evaluated the clinical significance and prognostic impact of thrombospondin-2 (THBS2) protein, A.K.A. TSP2, which encoded by THBS2 gene.
THBS2 immunostaining was performed in 340 UCs of upper urinary tract (UC-UUTs) and 295 UCBs; subsequently, both groups were dichotomized into high- and low-expression subgroups. Moreover, statistical analyses were performed to correlate the association between THBS2 expression and clinicopathological parameters with two survival indexes: disease-specific survival (DSS) and metastasis-free survival (MeFS).
High THBS2 immunoexpression was significantly associated with advanced primary tumor status, nodal metastasis, and vascular invasion in both UC-UUT and UCB groups (all P ≤ .001). In addition, THBS2 overexpression was linked to adverse DSS and MeFS in univariate analyses and served as an independent prognosticator indicating poor outcomes in both groups in multivariate analyses.
THBS2 may play a crucial role in UC progression and may be a novel prognostic marker. Additional investigations to elucidate the molecular pathway are necessary for developing potential THBS2-targeted therapies for UCs.
尿路上皮癌(UC)是一种肿瘤,尤其是膀胱癌,全球各地的人都可能受其影响。由于晚期UC经常复发且预后不良,因此阐明其详细的肿瘤生物学特性并发现潜在的治疗靶点对于制定治疗策略至关重要。通过挖掘美国国立生物技术信息中心基因表达综合数据库(GEO,NCBI)中已发表的膀胱尿路上皮癌(UCB)转录组数据集(GSE31684),我们发现在与结构分子活性相关的基因(GO:0005198)中,THBS2是上调最显著的基因。因此,我们评估了由THBS2基因编码的血小板反应蛋白-2(THBS2)蛋白(又称TSP2)的临床意义和预后影响。
对340例上尿路尿路上皮癌(UC-UUT)和295例UCB进行THBS2免疫染色;随后,将两组均分为高表达和低表达亚组。此外,进行统计分析以关联THBS2表达与临床病理参数之间的关系以及两个生存指标:疾病特异性生存(DSS)和无转移生存(MeFS)。
在UC-UUT组和UCB组中,THBS2高免疫表达均与原发性肿瘤进展、淋巴结转移和血管侵犯显著相关(所有P≤0.001)。此外,在单变量分析中,THBS2过表达与不良的DSS和MeFS相关,在多变量分析中,THBS2是两组预后不良的独立预后指标。
THBS2可能在UC进展中起关键作用,可能是一种新的预后标志物。为开发针对UC的潜在THBS2靶向疗法,有必要进行进一步研究以阐明其分子途径。